

Hideto Kameda

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4469141/hideto-kameda-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66

papers

1,361

citations

20

h-index

35

g-index

109

ext. papers

1,711

ext. citations

3.9

avg, IF

4.33

L-index

#	Paper	IF	Citations
66	Axial Spondyloarthritis in Japan.. <i>Current Rheumatology Reports</i> , 2022 , 1	4.9	
65	A Nationwide Questionnaire Survey on the Prevalence of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in Japan. <i>Modern Rheumatology</i> , 2021 ,	3.3	1
64	Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission. <i>Scientific Reports</i> , 2021 , 11, 6865	4.9	4
63	The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. <i>Drug Safety</i> , 2021 , 44, 711-722	5.1	3
62	Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study. <i>Arthritis and Rheumatology</i> , 2021 , 73, 110-120	9.5	44
61	Non-radiographic axial spondyloarthritis. <i>Modern Rheumatology</i> , 2021 , 31, 277-282	3.3	4
60	Finger Joint Cartilage Evaluated by Semiquantitative Ultrasound Score in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021 , 73, 173-179	4.7	1
59	2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. <i>Modern Rheumatology</i> , 2021 , 31, 29-33	3.3	7
58	Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). <i>Arthritis Research and Therapy</i> , 2021 , 23, 9	5.7	4
57	Good response to methotrexate is associated with a decrease in the gene expression of ABCG2, a drug transporter, in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2021 , 31, 1079-1086	3.3	3
56	Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD). <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	7
55	Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1663-1672	9.5	4
54	Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. <i>Arthritis Research and Therapy</i> , 2021 , 23, 231	5.7	3
53	2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. <i>Respiratory Investigation</i> , 2021 , 59, 709-740	3.4	2
52	Regulation of T cell differentiation by the AP-1 transcription factor JunB. <i>Immunological Medicine</i> , 2021 , 44, 197-203	3.7	4
51	A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis. <i>International Journal of Rheumatic Diseases</i> , 2020 , 23, 876-881	2.3	5
50	Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). <i>Rheumatology</i> , 2020 , 59, 2774-2784	3.9	12

49	Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 14	5.7	17
48	Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. <i>Rheumatology</i> , 2020 , 59, 3303-3313	3.9	25
47	Association of age with the non-achievement of clinical and functional remission in rheumatoid arthritis. <i>Scientific Reports</i> , 2020 , 10, 15277	4.9	1
46	Development and exacerbation of pulmonary nontuberculous mycobacterial infection in patients with systemic autoimmune rheumatic diseases. <i>Modern Rheumatology</i> , 2020 , 30, 558-563	3.3	6
45	The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method. <i>Modern Rheumatology</i> , 2020 , 30, 525-531	3.3	4
44	Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA). <i>Modern Rheumatology</i> , 2020 , 30, 239-248	3.3	9
43	Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis. <i>Advances in Therapy</i> , 2019 , 36, 691-707	4.1	5
42	Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. <i>RMD Open</i> , 2019 , 5, e000876	5.9	14
41	Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. <i>Arthritis Research and Therapy</i> , 2019 , 21, 79	5.7	19
40	JunB plays a crucial role in development of regulatory T cells by promoting IL-2 signaling. <i>Mucosal Immunology</i> , 2019 , 12, 1104-1117	9.2	15
39	Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019 , 29, 31-40	3.3	56
38	Reply. <i>Arthritis Care and Research</i> , 2018 , 70, 1119	4.7	
37	A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. <i>Arthritis Research and Therapy</i> , 2018 , 20, 155	5.7	33
36	Consensus statements for medical practice: Biological agents and lung disease [Abridged English translation by the Japanese Respiratory Society]. <i>Respiratory Investigation</i> , 2017 , 55, 229-251	3.4	15
35	Global assessments of disease activity are age-dependent determinant factors of clinical remission in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 47, 310-314	5.3	12
34	Concordance of Patient-Reported Joint Symptoms, Physician-Examined Arthritic Signs, and Ultrasound-Detected Synovitis in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2017 , 69, 801-806	4.7	15
33	Bendamustine increases interleukin-10 secretion from B cells via p38 MAP kinase activation. <i>International Immunopharmacology</i> , 2016 , 39, 273-279	5.8	5
32	Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 945-7	2.4	29

31	Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial. <i>Modern Rheumatology</i> , 2014 , 24, 561-6	3.3	8
30	A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology. <i>Modern Rheumatology</i> , 2013 , 23, 297-303	3.3	10
29	Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. <i>Modern Rheumatology</i> , 2013 , 23, 97-103	3.3	8
28	Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs. <i>Modern Rheumatology</i> , 2013 , 23, 284-296	3.3	15
27	Consensus statement for the diagnosis and treatment of drug-induced lung injuries. <i>Respiratory Investigation</i> , 2013 , 51, 260-77	3.4	13 ⁰
26	A merged presentation of clinical and radiographic data using probability plots in a clinical trial, the JESMR study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 310-2	2.4	6
25	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. <i>Modern Rheumatology</i> , 2012 , 22, 186-194	3.3	5
24	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). <i>Modern Rheumatology</i> , 2012 , 22, 327-338	3.3	36
23	Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. <i>Journal of Rheumatology</i> , 2011 , 38, 1258-64	4.1	114
22	Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. <i>Internal Medicine</i> , 2011 , 50, 305-13	1.1	53
21	Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). <i>Modern Rheumatology</i> , 2011 , 21, 122-133 ³	3.3	57
20	Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. <i>Journal of Rheumatology</i> , 2011 , 38, 1585-92	4.1	68
19	Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2010 , 20, 337-342	3.3	9
18	The Japanese experience with biologic therapies for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2010 , 6, 644-52	8.1	79
17	Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. <i>Modern Rheumatology</i> , 2010 , 20, 531-538	3.3	56
16	Improvement of the HAQ score by infliximab treatment in patients with RA: its association with disease activity and joint destruction. <i>Modern Rheumatology</i> , 2009 , 19, 166-172	3.3	8
15	Notable difference between the development of vertebral fracture and osteonecrosis of the femoral head in patients treated with high-dose glucocorticoids for systemic rheumatic diseases. <i>Internal Medicine</i> , 2009 , 48, 1931-8	1.1	6
14	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). <i>Modern Rheumatology</i> , 2008 , 18, 146-152	3.3	58

13	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). <i>Modern Rheumatology</i> , 2008 , 18, 447-454	3.3	38
12	Molecular effects to human regulatory T cells by treatment with T cell activation inhibitor and TNF blockade. <i>FASEB Journal</i> , 2008 , 22, 1073.10	0.9	
11	Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. <i>Modern Rheumatology</i> , 2007 , 17, 92-97	3.3	23
10	Clinical significance of elevated serum levels of matrix metalloproteinase-3 and C-reactive protein in patients with rheumatoid arthritis. <i>APLAR Journal of Rheumatology</i> , 2007 , 10, 295-299		3
9	Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2007 , 26, 1585-9	3.9	37
8	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). <i>Modern Rheumatology</i> , 2007 , 17, 28-32	3.3	56
7	Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases. <i>Drug Target Insights</i> , 2007 , 2, 239-47	3.4	2
6	Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dermatomyositis. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2006 , 6, 409-15	2.2	25
5	Efficacy and safety of bucillamine, a d-penicillamine analogue, in patients with active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2006 , 16, 85-91	3.3	24
4	Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab. <i>Modern Rheumatology</i> , 2006 , 16, 381-388	3.3	16
3	Molecular abnormalities of T-cells in systemic lupus erythematosus. <i>APLAR Journal of Rheumatology</i> , 2006 , 9, 365-371		2
2	Impact of TNF inhibitors on rheumatoid arthritis. <i>Inflammation and Regeneration</i> , 2006 , 26, 148-159	10.9	2
1	Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab. <i>Modern Rheumatology</i> , 2006 , 16, 381-8	3.3	5